MedTrace Logo

Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI

NCT06275035 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2025-04-09

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.

Conditions

  • Neurocognitive Dysfunction

Interventions

DRUG

Memantine Oral Tablet

Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy

Sponsors & Collaborators

  • Tata Memorial Centre

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-22
Primary Completion
2026-01-31
Completion
2031-01-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06275035 on ClinicalTrials.gov